ABT
Abbott just added another trick to the diabetes toolbox
Abbott Laboratories got the FDA’s blessing on Tuesday for Libre Duo 10 Day, a continuous glucose-and-ketone monitoring system for diabetes patients ages two and up. Translation: the company now has the first wearable in the U.S. that can keep an eye on ketones continuously, instead of making patients do the old-school finger-prick / urine-test dance.
Why investors should care
This isn’t just a nerdy regulatory footnote. Abbott is turning a familiar glucose sensor into a more ambitious, potentially stickier product — and stickier products can mean more users, more integrations, and more time spent in Abbott’s ecosystem.
The device cleared the FDA through the De Novo pathway, which is basically the agency’s “new gadget, but not life-threateningly wild” lane. Abbott backed the approval with six clinical studies and more than 600 participants, and the company says the sensor can flag meaningful ketone changes while lasting up to 10 days.
The competitive ripple effect
Abbott also said it’s lining up integrations with automated insulin delivery systems, including:
- Beta Bionics’ iLet by the end of this year
- Sequel Med Tech’s twiist by the end of this year
- Insulet’s systems in 2027
- Tandem Diabetes Care’s systems in 2027
- MiniMed Group’s smart dosing systems in 2027
That’s where the plot thickens. William Blair argued the new sensor could be especially competitive in pediatrics once pump integrations kick in, and the note also suggested the announcement could hang over DexCom’s shares. In other words: Abbott just tossed a new gadget into an already crowded diabetes ring.
Big picture
For Abbott, this is the kind of approval that can quietly expand a franchise without the drama of a blockbuster drug launch. For investors, the key question is whether Libre Duo becomes a meaningful growth engine — or just another nice-to-have upgrade in a market where everyone is fighting to own your diabetes dashboard.